<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893332</url>
  </required_header>
  <id_info>
    <org_study_id>2016 15-1</org_study_id>
    <nct_id>NCT02893332</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)</brief_title>
  <acronym>Sindas</acronym>
  <official_title>Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To tested if the adding of consolidative SBRT to TKI in EGFR mutated patients with less than&#xD;
      or equal to 5 metastatic sites (primary + 5) will improve progression free survival (PFS)&#xD;
      compared to TKI alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is a randomized phase III trial of TKI versus consolidative Stereotactic Body&#xD;
      Radiation Therapy (SBRT) plus TKI for patients with Stage IV non-small cell lung cancer&#xD;
      (NSCLC).&#xD;
&#xD;
      Prior to accrual on the trial, patients with Stage IV NSCLC will be tested with positive EGFR&#xD;
      mutation. Patients who with fewer than or equal to 5 sites of oligometastatic disease will be&#xD;
      randomized toTKI or consolidative SBRT to all sites of disease (followed by TKI at the&#xD;
      medical oncologist's discretion). Choices of TKI will be determined by the medical oncologist&#xD;
      based on clinical appropriateness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    After interim analysis, IRB recommend termination.&#xD;
  </why_stopped>
  <start_date type="Actual">January 15, 2016</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluate the effect of TKI with or without SBRT on progression free survival,to describe local control and out-of-field disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>To evaluate overall survival after SBRT followed by maintenance chemotherapy in comparison to maintenance chemotherapy alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])</measure>
    <time_frame>4 years</time_frame>
    <description>Using CTCAE system to evaluate toxicity profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stage IV EGFR Mutated Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TKI without SBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.&#xD;
The oligometastatic disease will not receive SBRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKI with SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.&#xD;
SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation: SBRT</intervention_name>
    <description>A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).</description>
    <arm_group_label>TKI with SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI (Gefitinib or Tarceva )</intervention_name>
    <description>A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.</description>
    <arm_group_label>TKI with SBRT</arm_group_label>
    <arm_group_label>TKI without SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed metastatic lung adenocarcinoma (recurrent or de novo) harboring&#xD;
             sensitizing EGFR mutations (L858R, exon 19 deletion, G719A, L861Q, S768I, exon 19&#xD;
             insertions) with oligometastatic disease (≤5 discrete lesions of disease irrespective&#xD;
             of location, inclusive of the primary lesion):&#xD;
&#xD;
               -  all sites of disease must be amenable to definitive treatment with a local&#xD;
                  therapy (surgical resection, stereotactic radiosurgery, ablation and conventional&#xD;
                  radiation therapy) as determined by surgery, interventional radiology and&#xD;
                  radiation oncology&#xD;
&#xD;
               -  all intrathoracic lymph nodes (including hilar, mediastinal, and supraclavicular&#xD;
                  nodal disease) are considered 1 discrete lesion.&#xD;
&#xD;
          -  No brain metastasis is allowed.&#xD;
&#xD;
          -  Patients already started on erlotinib are eligible as long as their sites of disease&#xD;
             are determined to be eligible for definitive local therapy by consensus of the&#xD;
             principal investigators within 12 weeks of the patient first taking erlotinib.&#xD;
&#xD;
          -  Lung adenocarcinoma histology confirmed&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 70%&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function, as specified below:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
               -  Platelets ≥ 100 x 109/L&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients&#xD;
                  with documented Gilbert's Syndrome)&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min&#xD;
                  for patients with creatinine levels above institutional normal.&#xD;
&#xD;
          -  For women of child-bearing potential, negative pregnancy test within 14 days prior to&#xD;
             starting treatment&#xD;
&#xD;
          -  Men and women of childbearing age must be willing to use effective contraception while&#xD;
             on treatment and for at least 3 months thereafter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with TKI prior to developing metastatic disease&#xD;
&#xD;
          -  Malignant pleural effusion or pleural disease&#xD;
&#xD;
          -  Leptomeningeal disease or brain metastasis.&#xD;
&#xD;
          -  Any site of disease that is not amenable to definitively local therapy including&#xD;
             surgery or radiation therapy&#xD;
&#xD;
          -  Women who are breastfeeding or pregnant&#xD;
&#xD;
          -  Concurrent malignancies other than non-melanoma skin cancer that require active&#xD;
             ongoing treatment.&#xD;
&#xD;
          -  Any medical co-morbidities that would preclude surgery or radiation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Zeng, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sichuan Provincial People Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sichuan PPH, Cancer Center</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>710062</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>ming zeng, MD</investigator_full_name>
    <investigator_title>Director of Cancer Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

